

## Implication of Covid-19 Infection on PRP Extraction in a Patient Suffering from Knee Osteoarthritis

Pooja Pithadia<sup>1</sup> and Sharmila Tulpule<sup>2\*</sup>

<sup>1</sup>Biochemist at Medica Pain Management Clinic London, Harley Street

<sup>2</sup>Orthopaedic Doctor, Orthobiologix Dubai

**\*Corresponding author:** Pithadia Pooja, Biochemist at Medica Pain Management Clinic London, Harley Street

**Citation:** Pithadia P, Tulpule S. (2023) Implication of Covid-19 Infection on PRP Extraction in a Patient Suffering from Knee Osteoarthritis. J Stem Cell Res. 4(1):1-7.

**Received:** January 30, 2023 | **Published:** February 15, 2023

**Copyright** © 2023 by Pithadia P. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

#### Background

Knee osteoarthritis (KOA) is one of the most prevalent degenerative diseases that cause pain and disability. None of the currently available treatments reverses or heals the degenerative nature of this condition. There were many research studies on the efficacy of PRP therapy in early KOA patients. However, there was no clinical study on its extraction or administration in a COVID-19 patient with KOA. Hence, the main objective of this observational study was to analyse the implication of COVID-19 infection on PRP extraction along with Red Blood Cell Distribution Width (RDW) and platelet count levels.

#### Methods & Findings

We present a case report of knee osteoarthritis administered with two ultrasound-guided Platelet-Rich Plasma (PRP) injections pre and post covid-19 infection.

As the patient was affected with COVID-19 infection immediately after a week of the first PRP session, he was finally administered the second dose only after 21 days, followed by the third final dose after 6 weeks.

**Case Report** | Pithadia P, et al. J Stem Cell Res. 2023, 4(1)-44.

**DOI:** [https://doi.org/10.52793/JSCR.2023.4\(1\)-44](https://doi.org/10.52793/JSCR.2023.4(1)-44)

## Conclusion

As COVID-19 infection affects the lungs, there was an increase in hematocrit values, leading to difficulty in plasma separation. Furthermore, there was an elevated level of RDW with the change in platelet count.

## Keywords

PRP therapy; Knee Osteoarthritis; COVID-19; RDW

## Introduction

Knee osteoarthritis (KOA) is ubiquitous in 10% of males and 13% of females among the elders due to a gradual increase in ageing, obesity, and life expectancy [1]. It was estimated that this condition could affect over 10% of the population across the world [2,3], with a lifetime risk of 45% [3,4]. Since none of the currently existing treatments reverses or heal the degenerative nature of this condition [6];there has been considerable attention on non-surgical regenerative injections.Unlike other conservative treatments, Regenerative cell therapy uses the anti-inflammatory and healing properties of a patient's cells to heal the inflamed and painful joint area. [6]. Platelet Rich Plasma (PRP) therapy, one of the types of regenerative cell treatment, is being evaluated to relieve knee osteoarthritis symptomatic pain and inflammation [7,8].

Autologous PRP mainly consists of platelets with varied bioactive substances, including growth factors, TGF- $\beta$ , VEGF, IGF1, alfa granules, etc. It plays a significant role in repairing the tissues naturally and promotes tissue regeneration [9].PRP therapy has several advantages over other treatments concerning non-invasiveness, non-immunogenic, cost-effectiveness, and relatively safe [10].Furthermore, patients undergoing PRP treatment revealed no adverse side effects [11]. Some publications have even stated that PRP therapy could be a promising alternative for knee osteoarthritis treatment [12–14]. Although regenerative treatment was reported to be safe in patients with moderate-to-severe KOA for 12 months post-COVID-19 vaccination, there was no clinical study on the effect of PRP immediately after COVID-19 infection [15].

Patients with COVID-19 were found to be associated with thrombocytopenia (lower platelet count in the blood).The reason for this lower platelet count was reported to be the utilisation of platelets in forming pulmonary thrombito prevent the occurrence of viremia through the bloodstream [5]. It was anticipated that damaged endothelium would result in platelet activation, thrombi formation, and platelet consumption [19]. There was a significant increase in venous thromboembolism among people hospitalised due to COVID-19 infection [20].Furthermore, this study reported the Red Blood Cell Distribution Width (RDW) level and thrombocytopenia rates since low platelet count was estimated to be about 5-41.7% in patients with COVID-19 [19]. As there was a drop in platelet count, the main objective of this current case study was to describe the implication of COVID-19 infection on PRP preparation, especially in a patient suffering from KOA.

## Case Presentation

An Irish man, 45 years old, presented to a Medica Pain Management Clinic with a grade-2 left knee osteoarthritis diagnosis, with limited range of motion and pain onset around five months before. He had no knee traumas in the last year. As a diabetic patient, he consumed only a non-dairy, gluten-free diet. The patient underwent a complete KOA rehabilitation program and intra-articular injections of corticosteroids and hyaluronic acid with no significant outcomes. In addition, Naproxen(1000 mg) and Neurofen (non-steroidal anti-inflammatory drugs (NSAIDs) (400 mg) were consumed twice daily. He also had no significant improvement in pain for the past 3 months.

Hence, the patient visited the Medica Pain Management clinic for a consultation on possible non-surgical treatments for his left knee pain, where he was recommended platelet-rich plasma injections. Both written information and proper education were provided regarding PRP and its use within knee osteoarthritis, including the possible risks involved. The patient was already diagnosed with grade-2 knee osteoarthritis and failed conservative treatments, so he was assessed as a suitable candidate for ultrasound-guided PRP injections. Formal written informed consent was received from the patient before the commencement of treatment.

## Treatment


### PRP Preparation & Administration

The PRP was extracted from the 15ml of the patient's peripheral blood via swing centrifugation as per the established protocol of the Y-Cell Bio-kit (Y-cell Bio-kit for PRP extraction: [http://www.ycellbio.com/bbs/content.php?co\\_id=ycellprp\\_en](http://www.ycellbio.com/bbs/content.php?co_id=ycellprp_en)) and administered intra-articularly using ultra-sound guidance for precision. The procedure was conducted aseptically. No adverse events or major complications were reported during PRP therapy except mild discomfort and pain at the injection site. It lasted only ten minutes and was relieved by its own [15]. However, the doctor prescribed Co-Codamol (30/500mg) to be taken twice daily if the pain persists.

However, after a week, the patient was affected by COVID-19 infection. Hence, he was administered the second final dose only after 21 days instead of 7 days. After 21 days, his PRP sample was not fit for administration due to difficulty processing the hemolysed sample. The final third dose of PRP was administered after 6 weeks post-COVID-19 infection.

## Results

Before the COVID-19 infection, the platelet-rich plasma appeared to be clear. However, during the second final dose of PRP (21 days post-COVID-19 infection), the platelet-rich plasma appeared to be unclear despite performing centrifugation three times (Figures 1 & 2), which returned to normal level after 6 weeks post-COVID-19 infection.



**Figure 1:** PRP extraction before COVID-19 infection.



**Figure 2:** PRP extraction after COVID-19 infection.

Parameters	First PRP Injection (Before COVID-19)	Second PRP Injection (21 days after COVID-19)	Third PRP Injection (6 weeks after COVID-19)
Platelet baseline	285 10 <sup>9</sup> /L	223 10 <sup>9</sup> /L	272 10 <sup>9</sup> /L
Platelet cell count	630 10 <sup>9</sup> /L	267 10 <sup>9</sup> /L	499 10 <sup>9</sup> /L
Haemoglobin	14.2	12.55	13.7
Normal haemoglobin range	13.0-17.0	13.0-17.1	13.0-17.2
RDW - SD	38.9	47.2	46.8
Normal RDW – SD range	35.1-43.9	35.1-43.10	35.1-43.11
RDW (CV)	12.7	14.55	15
Normal RDW (CV) range	11.6- 14.0	11.6- 14.1	11.6- 14.2

**Table 1:** Cell Count Analysis.

Table 1 highlights the comparative study of PRP levels before and after COVID-19 disease. The COVID-19

**Case Report** | Pithadia P, et al. J Stem Cell Res.2023, 4(1)-44.

**DOI:** [https://doi.org/10.52793/JSCR.2023.4\(1\)-44](https://doi.org/10.52793/JSCR.2023.4(1)-44)

disease was associated with low haemoglobin saturation, elevated RDW level, and an increase in platelets level, which returned to normal levels after a few weeks.

## Discussion

Since the patient was still experiencing COVID-19 symptoms, especially weakness, there was a change in plasma content. COVID-19 infection is known to affect the lungs followed by walls thickening. As a result, there would be an increase in hematocrit values due to which plasma separation proved difficult, and PRP needed to be clarified. During the PRP extraction, various factors contribute to the platelet concentration gradient, such as the size of platelets, the biological difference among individuals, and hematocrit variability [16]. Some studies report that the hematocrit and total platelet count influence the platelet concentration of the PRP [17]. Blood with a low per cent hematocrit has more plasma available, diluting the platelet concentration in plasma [16]. Pan and colleagues observed a decrease in RDW and an increase in haemoglobin and hematocrit levels in COVID-19 patients [18].

Furthermore, non-severe and COVID-19 survivors have a higher platelet count than severe and non-COVID-19 survivors. A thrombocytopenia condition in COVID-19 patients may be associated with a higher risk of death due to platelet consumption and coagulation abnormalities, including high fibrinogen and D-dimer levels. However, it was not the risk factor for mortality [19, 20]. Similarly, a higher level of RDW was characterised by the overproduction of tumor necrosis factor and interleukins, followed by increased inflammation, elevated vascular permeability, and anticoagulant-procoagulant imbalance in patients with COVID-19 [21]. This was the first direct study that revealed the implication of COVID-19 infection on PRP extraction.

## Study limitations

The current study's limitations include the need for follow-up, objective assessment of the interventional outcomes, and lack of a control group as it was a case study. There has been a lack of high-quality research studies on regenerative treatment for more than two years with multiple trial settings for knee osteoarthritis treatment.

## Future investigations

The current observational study is in progress, thereby reporting the efficacy of PRP treatment on knee osteoarthritis post-COVID-19 infection in the following research paper.

## Acknowledgements

The participating patient had given his consent for the same. It is not a clinical trial; this was a study to check improvement in patient life after treatment was given; this treatment is already approved.

## Funding

This research received no external funding.

## Competing and Conflicting Interests

The authors declare that they have no competing interests.

**Case Report** | Pithadia P, et al. *J Stem Cell Res.* 2023, 4(1)-44.

**DOI:** [https://doi.org/10.52793/JSCR.2023.4\(1\)-44](https://doi.org/10.52793/JSCR.2023.4(1)-44)

## Abbreviations

- KOA – Knee Osteoarthritis
- PRP - Platelet-Rich Plasma
- RDW - Red Blood Cell Distribution Width

## References

1. Moghimi N, Rahmani K, Delpisheh A, Saidi A, Azadi NA, et al. (2019) Risk factors of knee osteoarthritis: A case-control study. *Pakistan J Med Sci.* 35(3):636-40.
2. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, D et al. (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum.* 58(1):26–35.
3. Rodríguez-Merchán EC.(2022) Intra-Articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Review of Their Current Molecular Mechanisms of Action and Their Degree of Efficacy. *Int J Mol Sci.* 23(3):1301.
4. Losina E, Weinstein AM, Reichmann WM, Burbine SA, Solomon DH, et al. (2013) Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. *Arthritis Care Res.* 65(5):703–11.
5. Thachil J. (2020) What does monitoring platelet counts in COVID-19 teach us? *J Thromb Haemost.* 18(8):2071–72
6. Fodor PB, Paulseth SG. (2016) Adipose Derived Stromal Cell (ADSC) Injections for Pain Management of Osteoarthritis in the Human Knee Joint. *Aesthet Surg J.* 36(2):229-36.
7. Laudy AB, Bakker EW, Rekers M, Moen MH. (2015) Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. *Br J Sports Med.* 49(10): 657-72.
8. Filardo G, Kon E, Buda R, Timoncini A, Di Martino A, et al. (2011) Platelet rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. *Knee Surg Sports Traumatol Arthrosc* 19(4): 528-35.
9. Randelli PS, Arrigoni P, Cabitza P, Volpi P, Mafulli N. (2008) Autologous platelet rich plasma for arthroscopic rotator cuff repair. A pilot study. *Disabil. Rehabil.* 30(20-22): 1584–89.
10. Kim. (2019) Effect of platelet–rich plasma on the degenerative rotator cuff tendinopathy according to the compositions. *J. Ortho. Surg. Res.* 14(1):408.
11. Chaudhary D, Kumar R, Kalla R. (2016) Functional outcome and results of platelet rich plasma (PRP) in rotator cuff tendinopathy. *Int. J. Sci. Res.* 5(1):2277– 79
12. Bennell KL, Hunter DJ, Paterson KL. (2017) Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis. *Curr Rheumatol. Rep.* 19(5): 24.
13. Shen L, Yuan T, Chen S, Xie X, Zhang C. (2017) The temporal effect of platelet rich plasma on pain and physical function in the treatment of knee osteoarthritis: Systematic review and meta-analysis of randomized controlled trials. *J. Orthop. Surg. Res.* 12:16.
14. Knop E, Paula LE, Fuller R. (2016) Platelet-rich plasma for osteoarthritis treatment. *Rev. Bras. Reumatol. Engl. Ed.* 56(2):152–64.
15. Pithadia P, Tulpule S, Rehman MU, Mahmoud E, Singh M. (2022) Efficacy and Safety of Regenerative Treatment in Knee Osteoarthritis Patients after COVID-19 Vaccination. *J Stem Cell Res.* 3(3):38.
16. Dhurat R, Sukesh M. (2014) Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. *J Cutan Aesthet Surg.* 7(4):189-97.
17. Woodell-May JE, Ridderman DN, Swift MJ, Higgins J. (2005) Producing accurate platelet counts for platelet rich plasma: Validation of a hematology analyzer and preparation techniques for counting. *J Craniofac Surg.* 16(5):749–59.

18. Pan Y, Ye G, Zeng X, Liu G, Zeng X, et al. (2020) Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia? *Clin Transl Med.* 10(1): 161-68.
19. Fard MB, Fard SB, Ramazi S, Atashi A, et al. (2021) Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity. *Thromb J.* 19(1):59.
20. Wool GD, Miller JL. (2020) The impact of COVID-19 disease on platelets and coagulation. *Pathobiology.* 88(1):15-27.
21. Ramachandran P, Gajendran M, Perisetti A, Elkholy KO, Chakraborti A, et al. (2021) Red blood cell distribution width in hospitalized COVID-19 patients. *Front Med (Lausanne).* 7:8-582403.